DrugPatentWatch Database Preview

Ipilimumab - Biologic Drug Details

« Back to Dashboard

Summary for ipilimumab

Tradenames:	1
Patents:	168
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ipilimumab

Recent Clinical Trials for ipilimumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
OncoImmune, Inc.	Phase 1/Phase 2
Huntsman Cancer Institute	Phase 1/Phase 2
Stanford University	Phase 2

See all ipilimumab clinical trials

Pharmacology for ipilimumab

Mechanism of Action	CTLA-4-directed Antibody Interactions
Physiological Effect	Increased T Lymphocyte Activation

Patent Text Search: US Patents for ipilimumab

These patents were identified by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Bristol Myers Squibb	YERVOY	ipilimumab	INJECTABLE; INJECTION	125377	001	2011-03-25		Medarex, Inc. (Princeton, NJ)	2025-11-08	RX	Orphan	search
Bristol Myers Squibb	YERVOY	ipilimumab	INJECTABLE; INJECTION	125377	001	2011-03-25		Gilead Sciences, Inc. (Foster City, CA)	2026-07-21	RX	Orphan	search
Bristol Myers Squibb	YERVOY	ipilimumab	INJECTABLE; INJECTION	125377	001	2011-03-25		Gilead Sciences, Inc. (Foster City, CA)	2027-07-06	RX	Orphan	search
Bristol Myers Squibb	YERVOY	ipilimumab	INJECTABLE; INJECTION	125377	001	2011-03-25		Bristol-Myers Squibb Company (Princeton, NJ)	2028-08-01	RX	Orphan	search
Bristol Myers Squibb	YERVOY	ipilimumab	INJECTABLE; INJECTION	125377	001	2011-03-25		Aegis Therapeutics LLC (San Diego, CA)	2026-06-23	RX	Orphan	search
Bristol Myers Squibb	YERVOY	ipilimumab	INJECTABLE; INJECTION	125377	001	2011-03-25		Gilead Sciences, Inc. (Foster City, CA)	2026-07-07	RX	Orphan	search
Bristol Myers Squibb	YERVOY	ipilimumab	INJECTABLE; INJECTION	125377	001	2011-03-25		Pfizer Inc. (New York, NY)	2039-02-26	RX	Orphan	search

International Patents for ipilimumab

Country	Patent Number	Estimated Expiration
European Patent Office	2970369
Australia	2013337578
Israel	200550
Ukraine	101312
Canada	2812129
Australia	2014214843
Australia	2013263076

Supplementary Protection Certificates for ipilimumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
15C/058	Belgium		PRODUCT NAME: COBICISTAT; AUTHORISATION NUMBER AND DATE: EU/1/13/830/001
4 1-2017	Slovakia		PRODUCT NAME: KOBICISTAT VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM/DARUNAVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/967 20141121
17003	Norway		PRODUCT NAME: KOBICISTAT ELLER FARMASOEYTISK AKSEPTABELT SALT DERAV OG TENOFOVIR ALAFENAMID ELLER FARMASOEYTISK AKSEPTABELT SALT DERAV, SPESIELT TENOFOVIR ALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061 20151209
0861	Netherlands		PRODUCT NAME: COBICISTAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN EN DARUNAVIR, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN. IN HET BIJZONDER DARUNAVIRETHANOLAAT; REGISTRATION NO/DATE: EU/1/14/967 20141121
15/058	Ireland		PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/830/001-EU/1/13/830/002 20130524
0859	Netherlands		PRODUCT NAME: COBICISTAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN ATAZANAVIR, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER ATAZANAVIRSULFAAT; REGISTRATION NO/DATE: EU/1/15/1025 20150715
01530064	Spain		PRODUCT NAME: COBICISTAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/13/830; DATE OF AUTHORISATION: 20130524; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/830; DATE OF FIRST AUTHORISATION IN EEA: 20130524